You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30-expression

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Circulating Tumor Cells

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Sample
  • Nice, France
    CHU de Nice
Dec 5, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • CAR.CD30 T cells
  • Chapel Hill, North Carolina
  • +2 more
Mar 16, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +7 more
    • Anti CD30 CAR-T Cell Injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of medicine, Zhejiang Uni
    Jan 12, 2022

    Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

    Active, not recruiting
    • Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +4 more
    Apr 3, 2022

    Brentuximab Vedotin Intravenous Infusion "Untreated

    Active, not recruiting
    • Untreated CD30-Positive Hodgkin's Lymphoma
    • Brentuximab vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Mar 24, 2022

    Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

    Active, not recruiting
    • Hodgkin's Lymphoma
    • Non-Hodgkin's Lymphoma
    • autologous CAR.CD30 EBV specific-CTLs
    • Houston, Texas
    • +1 more
    Feb 4, 2022

    Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

    Recruiting
    • Classical Hodgkin Lymphoma
    • +2 more
    • Duarte, California
    • +4 more
    Jun 27, 2022

    NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

    Not yet recruiting
    • NK/T Cell Lymphoma Nos
    • Brentuximab Vedotin in Combination with Tislelizumab
    • (no location specified)
    Apr 6, 2022

    Hematologic Malignancies Trial in Assiut (CD56)

    Recruiting
    • Hematologic Malignancies
    • CD56
    • Assiut, Egypt
    • +1 more
    Jul 20, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin)

    Not yet recruiting
    • T-Cell Lymphoma
    • Brentuximab vedotin
    • (no location specified)
    Jun 30, 2022

    Hodgkin Lymphoma, Adult Trial in Chapel Hill (ATLCAR.CD30, Bendamustine, Fludarabine)

    No longer available
    • Hodgkin Lymphoma, Adult
    • ATLCAR.CD30
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2021

    Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

    Active, not recruiting
    • Recurrent Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Brentuximab Vedotin
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    Feb 17, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

    Not yet recruiting
    • T-Cell Lymphoma
    • (no location specified)
    Jul 22, 2022

    Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

    Active, not recruiting
    • Hodgkin Disease
    • +8 more
    • ATLCAR.CD30 cells
    • Chapel Hill, North Carolina
    • +1 more
    Mar 2, 2022

    Rheumatoid Arthritis Trial in Los Angeles, Chicago, London (Tc 99m tilmanocept)

    Recruiting
    • Rheumatoid Arthritis
    • Tc 99m tilmanocept
    • Los Angeles, California
    • +3 more
    Sep 13, 2022

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022

    Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

    Terminated
    • Hodgkin Lymphoma
    • +2 more
    • brentuximab vedotin
    • Anaheim, California
    • +18 more
    Dec 6, 2022

    Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

    Recruiting
    • Recurrent Classic Hodgkin Lymphoma
    • Brentuximab Vedotin
    • Nivolumab
    • Duarte, California
      City of Hope Medical Center
    Feb 16, 2022

    Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

    Recruiting
    • Recurrent Follicular Lymphoma
    • Refractory Follicular Lymphoma
    • Bendamustine Hydrochloride
    • Brentuximab Vedotin
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Dec 17, 2021

    Solid Tumors, Adult Trial in Dallas, Hangzhou (HF158K1 /Arm 2 mg/m², HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m²)

    Not yet recruiting
    • Solid Tumors, Adult
    • HF158K1 /Arm 2 mg/m²
    • +5 more
    • Dallas, Texas
    • +2 more
    May 6, 2023

    CD160 Expression in Corneal Vessels

    Not yet recruiting
    • Corneal Graft Rejection
    • +3 more
    • Immunohistochemistry and clinical analyses on patients and corneas
    • Reims, France
      Damien JOLLY
    Aug 11, 2021